Published on Roswell Park Cancer Institute (http://www.roswellpark.org)

Associate Professor, Department of Medicine
Assistant Professor, Department of Immunology
Roswell Park Cancer Institute
Profile
Areas of Expertise: 
Lymphoma
Multiple myeloma
Research
Research Interests: 
Mechanisms associated with resistance to monoclonal antibodies in lymphoma patients
Developing new strategies to enhance the activity of therapies such as rituximab and other monoclonal antibodies
Background Information
Education and Training: 
MD - InstitutoTecnologico y de Estudio Superiores de Monterrey, Monterrey, Mexico
Residency: 
School of Medicine and Biomedical Sciences, State University of New York at Buffalo
Board Certification: 
Internal Medicine, American Board of Internal Medicine
Medical Oncology, American Board of Internal Medicine
Fellowships: 
Roswell Park Cancer Institute, Buffalo, NY
Publications
Publications: 
  • Ngamphaiboon N, Pukiat S, Kandimalla Y, Hernandez-Ilizaliturri FJ, Rooney JJ. Diffuse large B-cell lymphoma presenting as pancoast tumor. Journal of clinical oncology 2010; 28(16):e254-e256
  • Riaz W, Hernandez-Ilizaliturri FJ, Czuczman MS. Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms. Immunologic research 2010; 46(1-3):192-205
  • Sher T, Lee K, Block AW, Wood MT, Sood R, Bilgrami SA, Lawrence W, Miller A, Czuczman MS, Hernandez-Ilizaliturri F, Whitworth A, Lawrence D, Miller KC, Chanan-Khan AA. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leukemia and lymphoma 2010; 51(1):85-88
  • Wierda G, Nielsen T, Gupta I, Gorczyca M, Padmanabhan S, Hernandez-Ilizaliturri F, Griniute R, Hess G, Smolej L, Mayer J, Stilgenbauer S, Griskevicius L, Durig J, Kipps T, Russell C. Chemoimmunotherapy with ofatumumab, fludarabine and cyclophosphamide in previously untreated patients with chronic lymphocytic leukemia: A phase II international trial. Haematologica 2010; 95(Suppl. 2):Abstract #769
  • Wilson WH, Hernandez-Ilizaliturri FJ, Dunleavy K, Little RF, O'Connor OA. Novel disease targets and management approaches for diffuse large B-cell lymphoma. Leukemia and lymphoma 2010; 51(Suppl. 1):1-10
  • Wierda WG, Nielsen TG, Gupta I, Gorczyca M, Padmanabhan S, Hernandez-Ilizaliturri FJ, Griniute R, Hess G, Smolej L, Mayer J, Stilgenbauer S, Griskevicius L, Durig J, Kipps TJ, Russell CA. Ofatumumab combined with fludarabine and cyclophosphamide (O-FC) shows high activity in patients with previously untreated chronic lymphocytic leukemia: Results from a randomized, multicenter, international, two-dose, parallel-group phase II trial. Clinical lymphoma, myeloma and leukemia 2010; 10(3):8
  • Advani P, Ngamphaiboon N, Pukiat S, Chavez J, Deeb G, Elefante A, Hernandez-Ilizaliturri FJ. The expression of bcl-6 in diffuse large B cell lymphoma (DLBCL) is associated with improved progression free survival and overall survival following front-line rituximab-chemotherapy. Blood 2010; 116(21):5073
  • Barth M, Hernandez-Ilizaliturri FJ, Mavis C, Tsai P, Gibbs J, Deeb G, Czuczman MS. Ofatumumab, a fully human monoclonal antibody targeting CD20, demonstrates activity against and potentiates the anti-tumor activity of chemotherapy agents in rituximab-sensitive cell lines (RSCL), rituximab-resistant cell lines (RRCL), lymphoma xenografts, and primary tumor cells derived from patients with B-cell non-hodgkin lymphoma (NHL). Blood 2010; 116(21):3917
  • Derby L, Pendurti G, Deeb G, Sait S, Block A, Hernandez-Ilizaliturri FJ. Blastoid variant of mantle cell lymphoma (MCL) is associated with P53 abnormalities and have a shorter progression-free survival (PFS) and overall survival (OS) despite upfront chemo-immunotherapy followed by high dose chemotherapy and autologous stem cell support (HDC-ASCS). Blood 2010; 116(21):1773
  • Gu J, Hernandez-Ilizaliturri FJ, Kaufman GP, Mavis C, Czuczman MS. Carfilzomib (CFZ): A novel proteasome inhibitor that induces cell cycle arrest and cell death in rituximab-chemotherapy resistant lymphoma and potentiates the anti-tumor activity of chemotherapeutic agents. Blood 2010; 116(21):4908
  • Gu J, Ritesh P, Mavis C, Deeb G, Gibbs J, Hernandez-Ilizaliturri FJ, Czuczman MS. MLN2238, a novel and potent proteasome inhibitor, induces caspase-dependent cell death, cell-cycle arrest, and potentiates the anti-tumor activity of chemotherapy agents in rituximab-chemotherapy sensitive or resistant B-cell lymphoma cell lines. Blood 2010; 116(21):3939
  • Hernandez-Ilizaliturri FJ, Mavis C, Maraj I, Chisti MM, Gibbs J, Czuczman MS. Panobinostat, a novel histone deacetylase (HiDAC) inhibitor enhances the anti-tumor activity of bortezomib (BTZ) in rituximab-chemotherapy sensitive and resistant lymphoma cell lines. Blood 2010; 116(21):3936
  • Pukiat S, Ngamphaiboon N, Advani P, Chavez J, Deeb G, Elefante A, Hernandez-Ilizaliturri FJ. BCL-2 expression at the time of diagnosis affects the clinical outcome of patients with germinal center and non-germinal center diffuse large B-cell lymphoma (DLBCL) treated with chemo-immunotherpy. Blood 2010; 116(21):3130
  • Stein R, Chen S, Hernandez-Ilizaliturri FJ, Czuczman MS, Goldenberg DM. Milatuzumab improves efficacy of current treatments for B-cell malignancies. Blood 2010; 116(21):2837
  • Tsai P, Dvorak P, Bangia N, Olejniczak S, Czuczman MS, Hernandez-Ilizaliturri FJ. Rituximab resistance is associated with global downregulation of CD20 and CD54 in B-cell lymphoma cells: Implication of CD20 signaling on CD54. Blood 2010; 116(21):5077
  • Wierda WG, Hernandez-Ilizaliturri FJ, Padmanabhan S, Chan GW, Gupta IV, Gorczyca MM, Davis RL, Losic N, Lisby S, Cartron G, Trneny M, Kipps TJ, Mayer J, Robak T, Dyer MJ, Furman RR, Hillmen P, Stilgenbauer S, Williams CD, Osterborg A. Final analysis from the international trial of single-agent ofatumumab in patients with fludarabine-refractory chronic lymphocytic leukemia. Blood 2010; 116(21):921
  • Younes A, Hernandez F, Bociek RG, Kasamon YL, Lee P, Gore L, Buglio D, Copeland A. ENGAGE- 501: Phase 2 study investigating the role of epigenetic therapy with entinostat (SNDX-275) in relapsed and refractory hodgkin's lymphoma (HL), interim results. Blood 2010; 116(21):3959
  • Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai P, Gibbs JF, Czuczman MS. Activity of ofatumumab (OFA), a fully human monoclonal antibody targeting CD20, against rituximab (RTX)-sensitive (RSCL) and rituximab-resistant cell lines (RRCL), in vivo, and primary tumor cells derived from patients with B-cell lymphoma. Journal of clinical oncology 2010; 28(15 Suppl.):8095
  • Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, Macon WR, Witzig TE, Goy A, Czuczman MS. Response of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with nongerminal center B-cell phenotype to lenalidomide (L) alone or in combination with rituximab (R). Journal of clinical oncology 2010; 28(15 Suppl.):8038
  • Kaufman GP, Hernandez-Ilizaliturri FJ, Mavis C, Patil R, Czuczman MS. Evaluation of carfilzomib to disrupt the apoptotic threshold of B-cell lymphomas by targeting Bcl-2 family members and overcome rituximab (R) chemotherapy resistance. Journal of clinical oncology 2010; 28(15 Suppl.):e18514
  • Lamonica DM, Hahn T, Drumsta D, Achakzai M, Czuczman MS, Hernandez-Ilizaliturri FJ. 18F-fluorodeoxglucose (FDG) positron emission tomography (PET) versus FLIPI as a predictor of therapy response in follicular lymphoma (FL) patients. Journal of clinical oncology 2010; 28(15 Suppl.):8102
  • Patil R, Hernandez-Ilizaliturri FJ, Elefante A, Czuczman MS. Body mass index (BMI) and obesity as a predictor of clinical outcome in patients with Hodgkin's lymphoma treated with AVBD. Journal of clinical oncology 2010; 28(15 Suppl.):8063
  • Riaz W, Hernandez-Ilizaliturri FJ, Mavis C, Tsai P, Czuczman MS. Efficacy of combination of rituximab (R), obatoclax (O), and bortezomib (B) against rituximab-sensitive (RSCL) and rituximab-resistant B-cell lymphoma cell lines (RRCL). Journal of clinical oncology 2010; 28(15 Suppl.):8094
  • Straus DJ, Duvic M, Horwitz SM, Hymes KB, Goy A, Hernandez-Ilizaliturri FJ, Feldman T, Wegner B, Myskowski P. Interim results of phase II trial of pegylated liposomal doxorubicin (PLD) followed by bexarotene in advanced cutaneous T-cell lymphoma (CTCL). Journal of clinical oncology 2010; 28(15 Suppl.):8053
  • Younes A, Rosen PJ, Hernandez-Ilizaliturri FJ, Bociek G, Kasamon YL, Copeland A, Lee GT. ENGAGE-501: Phase II study investigating the role of epigenetic therapy with entinostat (SNDX-275) in relapsed and refractory Hodgkin's lymphoma (HL). Journal of clinical oncology 2010; 28(15 Suppl.):TPS298
  • Chavez J, Czuczman MS, Hernandez-Ilizaliturri FJ. Biology and management of diffuse large B-cell lymphoma. Contemporary oncology 2010; 2(1):28-38
  • Olejniczak SH, Hernandez-Ilizaliturri FJ, Gibbs J, Clements JL, Mavis C, Riaz W, Bangia N, Belicha-Villanueva A, Blickwedehl J, Czuczman MS. Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells. Blood 2010; 116(25):5605-5614
  • Gerber H-P, Benjamin D, Carter PJ, McDonagh CF, Hernandez-Ilizaliturri FJ, Hayes B, Okeley N, Alley SC, McCormick R, Miyamoto J, Morris-Tilden C, Stone I, Kung-Sutherland M, Grewal IS. Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas. Blood 2009; 113(18):4352-4361
  • Goldenberg DM, Rossi EA, Stein R, Cardillo TM, Czuczman MS, Francisco JH-I, Hansen HJ, Chang C-H. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood 2009; 113(5):1062-1070
  • Hernandez-Ilizaliturri FJ, Czuczman MS. Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 1. current treatment approaches. Oncology (Williston Park, N.Y.) 2009; 23(6):546-553
  • Hernandez-Ilizaliturri FJ, Hernandez-Ilizaliturri FJ, Czuczman MS. Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 2. Novel therapeutic strategies. Oncology (Williston Park, N.Y.) 2009; 23(7):610-615
  • Khubchandani S, Czuczman MS, Hernandez-Ilizaliturri FJ. Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies. Current opinion in investigational drugs (London, England : 2000) 2009; 10(6):579-587
  • Castillo JJ, Ribera J-M, Pantanowitz L, Montoto S, Horwitz SM, Hernandez-Ilizaliturri F, Diez-Martin JL, Cwynarski K, Collins JA, Bower M, Bibas M, Beltran BE, Vose JM. Prognostic factors in patients with HIV-associated peripheral T-cell lymphoma: a multicenter study. American journal of hematology 2011; 86(3):256-261
  • Brem EA, Czuczman MS, Fetterly G, Gibbs JF, Deeb G, Hoskin P, Mavis C, Knight J, Campagna R, Iqbal A, Gu J, Riaz W, Bhat S, Olejniczak SH, Tsai PC, Khubchandani S, Thudium K, Hernandez-Ilizaliturri FJ. Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas. British journal of haematology 2011; 153(5):599-611
  • Chanan-Khan A, Zeldis JB, Wallace PK, Czuczman MS, Hernandez-Illatazurri F, Miller A, Padmanabhan S, Lawrence D, Miller KC, Lee K. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer 2011; 117(10):2127-2135
  • Sher T, Lee K, Iancu D, Masood A, Jamshed S, Lawrence W, Soniwala S, Sood R, Hong F, Hernandez-Ilizaliturri FJ, Czuczman MS, Wilding G, Tan W, Wood M, Manfredi D, Miller KC, Ailawadhi S, Chanan-Khan A. A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients. British journal of haematology 2011; 154(1):104-110
  • Wierda WG, Russell CA, Nielsen TG, Gupta I, Chan G, Chang CN, Gorczyca M, Padmanabhan S, Hernandez-Ilizaliturri FJ, Griniute R, Hess G, Smolej L, Mayer J, Stilgenbauer S, Griskevicius L, Durig J, Kipps TJ, on behalf of the 407 Study Investigators. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood 2011; 117(24):6450-6458
  • Benekli M, McCarthy PL Jr, Padmanabhan S, Battiwalla M, Bambach B, Hernandez-Ilizaliturri F, Czuczman MS, Younis T, Smiley SL, Hahn T. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma. Bone marrow transplantation 2008; 41(7):613-619
  • Hoppe RT, Love G, Maloney DG, Mansur D, Mauch PM, Moore JO, Schilder RJ, Weiss LM, Winter JN, Yahalom J, Zelenetz AD, Kaminski MS, Hudson MM, Advani RH, Ambinder RF, Bierman PJ, Bloomfield CD, Blum K, Dabaja B, Djulbegovic B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, National Comprehensive Cancer Network. Hodgkin disease/lymphoma. Journal of the National Comprehensive Cancer Network : JNCCN 2008; 6(6):594-622
  • Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, Czuczman MS. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression. Clinical cancer research 2008; 14(5):1550-1560
  • Patel M, Ailawadhi S, Hernandez-Ilizaliturri F, Wilding GE. Vascular endothelial growth factor polymorphisms in early-stage non-small-cell lung cancer. Journal of clinical oncology 2008; 26(19):3289-3290; author reply 3290
  • Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J, Wallace P, Czuczman MS. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. British journal of haematology 2008; 140(1):36-45
  • Maddipatla S, Hernandez-Ilizaliturri FJ, Knight J, Czuczman MS. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20. Clinical cancer research 2007; 13(15 Pt 1):4556-4564
  • Cruz RI, Hernandez-Ilizaliturri FJ, Olejniczak S, Deeb G, Knight J, Wallace P, Thurberg BL, Kennedy W, Czuczman MS. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma. Leukemia and lymphoma 2007; 48(12):2424-2436
  • Vinjamaram S, Czuczman MS, Hernandez-Ilizaliturri FJ. The use of galiximab in non-Hodgkin lymphoma. Clinical lymphoma and myeloma 2008; 8(5):277-282
  • Vaidyanathan G, Ngamphaiboon N, Hernandez-Ilizaliturri FJ. Clinical spectrum and prognosis of follicular lymphoma with blastoid transformation: case series and a review of the literature. Annals of hematology 2011; 90(8):955-962
  • Hoppe RT, Advani RH, Ai WYZ, Ambinder RF, Bello CM, Bierman PJ, Blum KA, Dabaja B, Duron Y, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Maloney DG, Mansur D, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Poppe M, Pro B, Weiss L, Winter JN, Yahalom J. Hodgkin lymphoma. Journal of the National Comprehensive Cancer Network : JNCCN 2011; 9(9):1020-1058
  • Ahluwalia MS, Klein K, Kuvshinoff BW, Hernandez-Ilizaliturri FJ, Wilding G, Smith JL, Battiwalla M. Improving Compliance with Guidelines for Venous Thromboembolism (VTE) Prophylaxis Significantly Reduces VTE Events. Blood 2008; 112(11):466
  • Ailawadhi S, Hernandez-Ilizaliturri FJ, Miner L, Bernstein ZP, Chanan-Khan A, Miller KC, Mohr A, Starostik P, Czuczman MS, Padmanabhan S. Differences in BCL-2 protein and t(14;18) in patients with primary Rituximab/Chemotherapy refractory diffuse large B-Cell lymphoma (DLBCL). Blood 2007; 110(11 Part 2):177B (Abstract #4433)
  • Ashraf U, Czuczman MS, Marvis C, Gibbs J, Hernandez-Ilizaliturri FJ. Entinostat (SNDX-275), a Novel DAC Inhibitor, Is Highly Effective in Rituximab- [Chemotherapy]-Sensitive or Rituximab-[Chemotherapy]-Resistant Lymphomas and Has Synergistic Anti-Tumor Activity When Combined with Bortezomib. Blood 2009; 114(22):1435-1436
  • Ashraf U, Elefante AN, Cruz R, Wallace PK, Czuczman MS, Hernandez-Ilizaliturri FJ. Emergence of rituximab-fludarabine resistance is associated with changes in CD20 antigen expression-and improved response to almetuzumab therapy in patients with chronic lymphocytic leukemia (CLL). Blood 2007; 110(11 Part 1):Abstract #2054
  • Ashraf U, Mahajan R, Hahn T, Smiley SL, McCarthy PL, Bernstein ZP, Chanan-Khan AA, Battiwala M, Czuczman MS, Hernandez-Lizaliturri FJ. The Effects of Rituximab Added to Front-Line or Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing High-Dose Chemotherapy (HDC) and Autologous Stem Cell Transplant (ASCT). Blood 2008; 112(11):415-416
  • Castillo J, Beltran B, Collins J, Diez-Martin JL, Hernandez-Ilizaliturri F, Horwitz SM, Vose JM. Clinicopathologic Characteristics of HIV-Associated Peripheral T-Cell Lymphoma. Blood 2009; 114(22):1509
  • Chavez J, Walsh M, Hernandez-Ilizaliturri FJ, Elefante A, Czuczman MS. Classification of Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) According to the Han's Criteria Defines Two Groups of Patients with Different Clinical Outcomes Following Systemic Rituximab-Multi Agent Anthracycline-Based Therapy. Blood 2009; 114(22):258
  • Cruz RI, Hernandez-Ilizaliturri FJ, Knight JM, Czuczman MS. CD52 over-expression affects rituximab-associated complement mediated cytotoxicity (CMC) but not antibody dependent cellular cytotoxicity (ADCC): Pre-clinical evidence targeting CD52 with alemtuzumab to reverse acquired resistance to rituximab in Non-Hodg. Proceedings of the American Association for Cancer Research Annual Meeting 2007; 48:980
  • Czuczman MS, Skipper M, Mohr A, Bernstein ZP, Hernandez-Ilizaliturri FJ, Chanan-Khan AA. Phase I/II study of rituxan (R) in combination with doxil (D) in patients (pts) with relapsing or refractory B-cell lymphoma: Clinical efficacy without cardiac toxicity. Blood 2007; 110(11 Part 1):Abstract #1369
  • Derby L, Hernandez-Ilizaliturri FJ, Segal BH, Knight J, Bushey J, Czuczman MS. Pegylated granulocyte colony stimulating factor (Peg-G-CSF) enhances mapatumumab-mediated antibody dependent cellular cytotoxicity (ADCC) against non-Hodgkin's lymphoma (NHL) cell lines independent of NADPH oxidase-derived reactive oxidant intermediates (ROIs). Blood 2007; 110(11 Part 2):Abstract #4519
  • Gruber EA, Czuczman MS, Olejniczak SH, Knight J, Hernandez-Ilizaliturri FJ. GX15-070 and bortezomib induce up-regulation of BH3 single domain pro-apoptotic proteins Puma and Noxa and is associated with synergistic anti-tumor activity in rituximab-sensitive, rituximab-resistant cell lines (RSCL and RRCL), and primary lymphoma patient specimens. Blood 2007; 110(11 Part 2):417A
  • Gruber EA, Czuczman MS, Olejniczak SH, Knight J, Hernandez-Ilizaliturri FJ. GX15-070 and bortezomib induce up-regulation of BH3 single domain pro-apoptotic proteins Puma and Noxa and is associated with synergistic anti-tumor activity in rituximab-sensitive, rituximab-resistant cell lines (RSCL and RRCL), and primary lymphoma patient specimens. Blood 2007; 110(11 Part 1):Abstract #1389
  • Hernandez-Ilizaliturri F, Tsio PC, Campagna R, Marvis C, Riaz W, Gruber E, Gibbs J, Czuczman MS. Obatoclax and Bortezomib Therapy Results in Disruption of the p53-Mediated Apoptosis/Autophagy Pathway and Is Associated with Potent Synergistic Anti-Tumor Activity against Rituximab-Chemotherapy-Sensitive and -Resistant B-Cell Lymphoma. Blood 2009; 114(22):121
  • Hernandez-Ilizaliturri FJ, Ali M, Knight J, Rustum YM, Czuczman MS. Methylseleninic acid (MSA) decreases DNA synthesis, induces cell death, and sensitizes both rituximab sensitive and rituximab-resistant non-Hodgkin's lymphoma cell lines to the anti-tumor activity of cisplatin and gemcitabine. Blood 2007; 110(11 Part 2):201B (Abstract #4517)
  • Hernandez-Ilizaliturri FJ, Khubchandani S, Olejniczak SH, Hoskin P, Czuczman MS. Strategies to overcoming rituximab-chemotherapy resistance by targeting the autophagy pathway using bortezomib in combination with the Bcl-2 inhibitor obatoclax in non-Hodgkin's lymphomas (NHL). Journal of clinical oncology 2009; 27(15 Suppl.):Abstract #8543
  • Hernandez-Ilizaliturri FJ, Khubchandani S, Olejniczak SH, Hosking P, Gruber E, Czuczman M. The BH3-Mimetic Obatoclax (GX15-070) Posses a Dual-Mechanism of Action and Induces Both Apoptosis and Autophagy-Dependent Cell Death of B Cell Non-Hodgkin's Lymphoma (B-NHL) Cells. Blood 2008; 112(11):226
  • Hernandez-Ilizaliturri FJ, Marvis C, Maraj I, Chisti MM, Gibbs J, Czuczman MS. The DAC Inhibitor, LBH589, Is Highly Effective in Both Rituximab- Sensitive and Rituximab. Resistant Lymphomas and Enhances the Anti-Tumor Activity of Bortezomib, Other Chemotherapy Agents, and Anti-CD20 Monoclonal Antibodies. Blood 2009; 114(22):1063
  • Maraj I, Hernandez-Ilizaliturri FJ, Chisti M, Czuczman MS. Efficacy of the DAC inhibitor LBH589 in both rituximab-sensitive and rituximab-resistant lymphomas and effect on the antitumor activity of chemotherapy agents, monoclonal antibodies, and bortezomib. Journal of clinical oncology 2009; 27(15 Suppl.):Abstract #8576
  • Olejniczak SH, Czuczman MS, Hoskin P, Gruber E, Hernandez-Ilizaliturri FJ. The BH3-mimetic GX15-070 induces autophagy-dependent cell death of therapy-sensitive and -resistant aggressive B cell non-Hodgkin's lymphoma (B-NHL). Proceedings of the American Association for Cancer Research Annual Meeting 2008; 49:797
  • Olejniczak SH, Hernandez-Ilizaliturri F, Belicha A, Blickwedehl J, Clements JS, Bangia N, Czuczman MS. Bortezomib induces Bak expression and cell death in non-Hodgkin's lymphoma cell lines that are both rituximab- and chemotherapy-resistant. Proceedings of the American Association for Cancer Research Annual Meeting 2007; 48:457
  • Olejniczak SH, Hernandez-Ilizaliturri FJ, Blickwedehl J, Bangia N, Clements JL, Czuczman MS. Bortezomib induces a pro-apoptotic Bcl-2 family protein expression profile necessary to kill therapy-resistant B cell non-Hodgkin's lymphoma (B-NHL). Proceedings of the American Association for Cancer Research Annual Meeting 2008; 49:1043
  • Padmanabhan S, Elefante A, Varadarajan P, Battiwaralla M, Bir A, Hahn T, Smiley S, Hernandez-Illizalitturi FJ, Miner L, Mohr A, Bernstein ZP, Chanan-Khan A, McCarthy P, Czuczman M. Outcomes of relapsed/refractory B-cell lymphoma is improved by salvage chemotherapy consisting of two to three cycles of dexamethasone (D), High Dose Ara-C (HA) and carboplatin (DHAC) with or without rituximab (R) followed by autologous stem cell transplantation. Blood 2007; 110(11 Part 2):364B-365B (Abstract #5130)
  • Ramanarayanan J, Krishnan GS, Czuczman MS, Hernandez-Izaliturri FJ. Efficacy and safety of rituximab in post transplant lymphoproliferative disorders (PTLD): Pooled analysis and review of literature. Blood 2007; 110(11 Part 1):Abstract #1084
  • Ramanarayanan J, Pahuja S, Elefante AN, Hernandez-Ilizaliturri FJ. Abrogation of tumor necrosis alpha (TNF-alpha) pathway by anti-TNF therapy in hematological malignancies. Journal of clinical oncology 2009; 27(15 Suppl.):Abstract #7093
  • Reddy N, Hernandez-Ilizaliturri FJ, Knight J, Myron CS. Lenalidomide enhances the biological activity of galiximab against non-Hogkin's lymphoma in vitro and in vivo. Blood 2007; 110(11 Part 1):Abstract #2353
  • Reddy NM, Hernandez-Ilizaliturri F, Roth M, Vaughan M, Deeb G, Czuczman MS. Lenalidomide enhances rituximab anti-tumor activity by inducing expansion, activation and tumor infiltration of Natural killer (NK) cells, as well as alters the tumor microenvironment and inhibits angiogenesis. Proceedings of the American Association for Cancer Research Annual Meeting 2007; 48:844-845
  • Ritesh P, Pahuja S, Chavez J, Braddy W, Skipper M, Bernstein ZP, Chanan-Khan A, Ramanarayanan J, Czuczman MS, Hernandez-Ilizaliturri FJ. Correlation of surface expression of CD11b or CD32 in polymorphonuclear cells (PMNs) and CD69 in natural killer cells (NK) with progression-free survival (PFS) following chemoimmunotherapy with rituximab and liposomal doxorubicin (LD) in patients (pts) with relapsed or refractory B-cell lymphoma. Journal of clinical oncology 2009; 27(15 Suppl.):Abstract #8583
  • Sher T, Miller KC, Ailawadhi S, Manfredi D, Wood M, Tan W, Wilding G, Liu H, Czuczman MS, Hernandez F, Hong F, Sood R, Soniwalla S, Lawrence W, ipd_10, Lee KP, Chanan-Khan A. Bortezomib in Combination with Pegylated Liposomal Doxorubicin and Thalidomide (VDT), An Effective Steroid Independent Regimen for Previously Untreated Multiple Myeloma Patients: Final Result of a Phase II Study. Blood 2009; 114(22):256
  • Tsai PC, Bangia N, Olejniczak S, Hernandez-Llizaliturri FJ, Czuczman M. The Acquirement of Rituximab Resistance Is Associated with a Global Downregulation of CD54 in B-Cell Lymphoma Cells: The Potential Role of Adhesion Molecules in Rituximab Anti-Tumor Activity. Blood 2008; 112(11):903-904
  • Tsai P-C, Hernandez-Ilizaliturri FJ, Olejniczak S, Knight J, Bangia N, Czuczman M. Effects of Interleukin 4 (IL-4) on CD20 expression in rituximab-sensitive (RSCL) and rituximab resistant cell lines (RRCL). Proceedings of the American Association for Cancer Research Annual Meeting 2007; 48:218
  • Tsai PC, Hernandez-Ilizaliturri FJ, Olejniczak SH, Naveen B, Czuczman MS. Modulation of CD20 expression in rituximab-sensitive (RSCL) and rituximab resistant cell lines (RRCL) using IL-4 and bryostatin-1. Blood 2007; 110(11 Part 1):Abstract #2619
  • Vinjamaram S, Hemandez-Ilizaliturri FJ, Retke S, Knight J, Czuczman MS. Targeting BH3-domain anti-apoptotic proteins with ABT-737 decreases DNA synthesis, induces cell death and sensitizes rituximab-sensitive and rituximab-resistant non-Hodgkin's lymphoma cell lines to the anti-tumor activity of chemotherapy agents. Blood 2007; 110(11 Part 2):418A (Abstract #1393)
  • Wierda WG, Kipps TJ, Durig J, Griskevicius L, Stilgenbauer S, Mayer J, Smolej L, Hess G, Griniute R, Hernandez-Ilizaliturri FJ, Padmanabhan S, Gorczyca M, Chan G, Gupta I, Andersen M, Strange C, Nielsen TG, Russell CA. Ofatumumab Combined with Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results From a Randomized, Multicenter, International, Two-Dose, Parallel Group, Phase II Trial. Blood 2009; 114(22):90-91
  • Batoo SA, Hernandez-Ilizaliturri F. The emerging role of lenalidomide in the management of lymphoid malignancies. Therapeutic advances in hematology 2011; 2(1):45-53
  • Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, MacOn WR, Goy A, Witzig TE, Czuczman MS. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer 2011; 117(22):5058-5066
  • Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai PC, Gibbs JF, Deeb G, Czuczman MS. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. British journal of haematology 2012; 156(4):490-498
  • Evens AM, Advani R, Lossos IS, Press OW, Vose JM, Hernandez-Ilizaliturri FJ, Robinson BK, Otis S, Dagan LN, Abdallah R, Kroll A, Sandoval J, Yarber JL, Foyil KV, Parker LM, Gordon LI, Leonard JP, Habermann TM, Bartlett NL. Lymphoma in Pregnancy: Excellent Fetal Outcomes and Maternal Survival in a Large Multicenter Analysis. Blood 2011; 118(21):45-46
  • Mavis C, Frys S, Gu J, Gibbs J, Czuczman MS, Hernandez-Ilizaliturri FJ. Entinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor Enhances the Anti-Tumor Activity of Bortezomib (BTZ) in Rituximab-Chemotherapy Sensitive and Resistant Lymphoma Cell Lines. Blood 2011; 118(21):1594
  • Straus DJ, Duvic M, Horwitz SM, Hymes KB, Goy A, Hernandez-Ilizaliturri FJ, Feldman T, Wegner B, Myskowski P. Final Results of Phase II Trial of Pegylated Liposomal Doxorubicin (PLD) Followed by Bexarotene (Bex) in Advanced Cutaneous T-Cell Lymphoma (CTCL). Blood 2011; 118(21):403-404
  • Tsai PC, Hernandez-Ilizaliturri FJ, Bangia N, Olejniczak SH, Czuczman MS. Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma. Clinical cancer research 2012; 18(4):1039-1050
  • Wierda WG, Jewell RC, Kipps TJ, Durig J, Griskevicius L, Stilgenbauer S, Smolej L, Hess G, Hernandez-Ilizaliturri FJ, Padmanabhan S, Fang L, Gorczyca MM, Chan GW, Gupta IV, Lisby S. Correlations Between Ofatumumab Exposure and Treatment Outcomes for patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Ofatumumab, Fludarabine, and Cyclophosphamide Chemoimmunotherapy. Blood 2011; 118(21):782-783
  • Younes A, Hernandez F, Bociek RG, Kasamon YL, Lee P, Gore L, Copeland AR. The HDAC Inhibitor Entinostat (SNDX-275) Induces Clinical Responses in Patients with Relapsed and Refractory Hodgkin's Lymphoma: Results of ENGAGE-501 Multicenter Phase 2 Study. Blood 2011; 118(21):1168
  • Hoppe RT, Advani RH, Ai WYZ, Ambinder RF, Aoun P, Bello CM, Bierman PJ, Blum KA, Chen R, Dabaja B, Duron Y, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Maloney DG, Mansur D, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Poppe M, Pro B, Winter JN, Yahalom J, Sundar H. Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network : JNCCN 2012; 10(5):589-597
  • Barth MJ, Pendurti G, Mavis C, Czuczman N, Skitzki JJ, Hernandez-Ilizaliturri FJ, Czuczman MS. Preclinical activity of ofatumumab (OFA) in mantle cell lymphoma (MCL) in vitro, ex vivo, and in vivo models. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #e18537
  • Dawar R, Barth MJ, Mavis C, Skitzki JJ, Czuczman MS, Klener P, Hernandez-Ilizaliturri FJ. Evaluation of MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, as a novel targeted agent with single-agent antitumor activity in mantle cell lymphoma (MCL) and Hodgkin lymphoma preclinical models. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #e18539
  • Jitawatanarat P, Dawar R, Chittawatanarat K, Batty N, Czuczman MS, Hernandez-Ilizaliturri FJ. Alternating non-cross-resistant multiagent chemotherapy (ANCRC) and high-dose chemotherapy followed by autologous stem cell support (HDC-ASCS) in first remission to improve outcome in patients with T-cell lymphoma. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #e18538
  • Ailawadhi S, Miller KC, Depaolo D, Whitworth A, Brady W, Czuczman M, Bernstein ZP, Hernandez-Ilizaliturri F, Padmanabhan S, Chanan-Khan A. Fludarabine Plus Thalidomide as Frontline Therapy for Newly Diagnosed Patients With Chronic Lymphocytic Leukemia (CLL). Haematologica 2008; 93(Suppl. 1):0086
  • Padmanabhan S, Block AW, Wallace P, Tan W, Nowak N, Varadarajan P, Barcos M, Hernandez F, Ketepalli S, Wilding G, Czuczman M, Chanan-Khan A. Concomitant z score and ZAP 70 along with ATM deletion identifies patients with poor survival from the RPCI Chronic Lymphocytic Leukemia Series: A correlation of treatment and survival of B-CLL patients with prognostic variables such as fish, ZAP70 expression, CGH. Haematologica 2008; 93(Suppl. 1):416 (Abstract #1053)
  • Dawar R, Hernandez-Ilizaliturri F. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL). Best practice and research. Clinical haematology 2012; 25(2):185-190
Referral
Email: 
Francisco.Hernandez@RoswellPark.org
Fax: 
716-845-3894
Source URL (retrieved on 05/18/2013 - 12:20pm): http://www.roswellpark.org/francisco-hernandez-ilizaliturri